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ABSTRACT 
 
Granulosa cell tumors comprise approximately 5% of all ovarian malignancy and account for 70% of malignant sex 
cord stromal tumors. Granulosa cell tumors have been diagnosed from infancy, the peak incidence being 
perimenopausal age. The potential of malignancy of these tumors is low, recurrence are often late and found in 10-
33% of cases. A   32-year-old female para 1 live 1 presented with large abdominal mass fourth time in her lifetime 
for which she underwent staging laparotomy with debulking surgery. Histopathology of mass collected which was 
suggestive of granulosa cell tumor. She had three laparotomy for  same region in the past. At 13 year of age she was 
diagnosed with a stage IA granulosa cell tumor (GCT) of the ovary first time. For which she underwent surgical 
staging and removal of adnexal mass, after that she was asymptomatic for 7 years. In 2003 she again presented with 
lump abdomen for which she underwent a resection of adnexal mass, histopathology was consistent with recurrent 
GCT. After second surgery she also received two cycles of chemotherapy. Despite adjuvant chemotherapy treatment 
the patient presented again after three years in 2006 with adnexal mass and was found to have a third  recurrence. 
For which she received 6 cycles of chemotherapy and mass was regressed. After four year in 2010 she again 
presented with lump abdomen for which she underwent surgical staging total abdominal hysterectomy with right 
salphingo ophorectomy with removal of mass. After five year in 2015 she again presented with lump abdomen for 
which surgical management was done. So over the 20 years this patient had multiple recurrences and progressive 
disease despite surgical and targeted treatment. In conclusion the long history of granulosa cell tumor highlights the 
importance of extended follow up of the patient. 
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Introduction  
Granulosa cell tumors (GCT) are derived from the 
granulosa cells of the ovary. They constitute 
approximately 5% of the ovarian tumors and more than 
70 % of the sex cordstromal tumors. Two distinct 
histological types—adult GCT (AGCT) and juvenile 
GCT (JGCT) are there which display different clinical 
and histopathological features. AGCTs are more 
commonly seen in perimenopausal and postmenopausal 
women, with a peak incidence at 50–55 years while 
JGCTs are rare tumors, representing 5 % of all GCTs 
and occurring in pre menarchal girls and young women 
[1].Granulose cell tumours arise from granulosa cells 
that are hormonally active stromal elements and 
responsible for production of estradiol. Adult granulose 
cell tumor are usually stage 1 at the time of diagnosis, 
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but it may recurs in 5 to 30 years after initial diagnosis 
while most juvenile granulosa cell tumors are clinically 
benign and only 10% recurs with in 5 year after the 
initial diagnosis. FOXL2 gene encodes the 
transcription factor which required for the normal 
development of the granulosa cell. Shah et al. in their 
study they found that somatic missense muation in 
FOXL2 (c.402C > G; p.C134W) in GCT. These 
mutations was seen in 86 of 89 (97%) adult GCT, 1 of 
10 (10%) juvenile GCT. The high frequency of these 
mutations suggests this mutation may be pathognomic 
for AGCT, and the absence of this mutation in JGCT 
shows that JGCT may be an entirely different tumor 
[2,3].Chromosomal abnormalities have also been 
recently evaluated in these tumors. Detected 
abnormalities of chromosome include trisomy 12, 
monosomy 22, and deletion of chromosome 6. Among 
juvenile granulosa cell tumors it has been identified by 
cytogenetic studies that trisomy 12 and a deletion in 
chromosome 6q plays a major role. BRCA1 and BRCA 
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2 mutations are not associated with these tumors. Few 
syndroms are associated with predisposition of GCT as 
Peutz Jeghers syndrome and Potters syndrome. While 
Ollier disease and Maffucci disease are associated with 
juvenile GCT [4]. 
 
Case Report  
A 32-year-old female para 1 live 1 presented with large 
abdominal mass for 2year for which she was admitted 
and evaluated. In past the patient had three 
laparotomies and two chemotherapy cycles for 
granulosa cell tumor. She was diagnosed with a 
granulosa cell tumor (GCT) of the right ovary in 1996 
for which she underwent left salphingo ophorectomy at 
our institution. No further treatment was given. The 
patient remained disease free for 7 years; however, in 
April 2003 she again noticed a lump in abdomen. A 
second exploration was performed and removal of the 
mass done along with staging and multiple biopsies 
were taken. This time again histopatholgy of mass 
consistent with recurrent GCT; however, the lymph 
nodes and biopsies were negative. The patient was 
treated with chemotherapy for two cycle (ICE regime 
constitutes ifophosaphamide, cisplatin and etoposide). 
After chemotherapy patient was asymptomatic for two 
years. 
In 2006 after two years of chemotherapy patient again 
presented with left adenexal mass for which CECT was 
done and USG guided FNAC was done and 
histopathology sent and found to be granulosa cell 
tumor. Patient wants conservative management this 
time so six cycles of chemotherapy was given. After 
chemotherapy patient was asymptomatic for three 
years. 
In 2010 after three years of chemotherapy she again 
noticed huge abdominal mass for which patient 
underwent staging laparotomy with total abdominal 
hysterectomy with right salphingo ophorectomy with 
omentectomy. After third surgery patient was 
asymptomatic for 3 years.  
Now in 2015 she again presented with large abdominal 
mass. On examination patient had 28 to 30 week gravid 
uterus size abdominopelvic mass which was firm in 
consistency and not mobile. Her tumor markers were in 
normal limits. USG and PET-CECT was done which 
was suggestive of a well defined heterogenous 
enhancing FDG avid complex (solid & cystic) mass 
lesion noted in the pelvis compressing the left ureter 
displacing the urinary bladder right anterolaterally and 
left kidney had hydrouretero nephrosis. This time 
patient underwent staging laparotpmy and debulking of 
mass. 
Peroperative findings – a large 15 x 15 cm 
encapsulated mass with increased vascularity was 
present in the pelvic area arising from left side. This 
time patient underwent removal of adexal mass along 
with infracolic omentectomy. 
On cut section – tumor had variegated consistency. 
Solid portion of tumor was granular grey yellow in 
color.  
Postoperative period was uneventful and patient 
discharged on 14 post operative day and referred to 
cancer center for chemotherapy  
 
Discussion 
GCTs are rare tumors which account for approximately 
2–3% of all ovarian cancer. They are associated with a 
favorable outcome and prognosis, especially when they 
are diagnosed and treated in the early stages. 
Björkholm et al reported in 1981 that the 5year survival 
rates were over 95% for stage I, 55% for stage II, and 
25% for stage III tumors [5]. Lauszus et al., reported 
that the survival rates for stage I at 5, 10 and 20 years 
were 94%, 82%, and 62%, respectively [6]. These 
studies conclude that GCTs tend to be associated with 
late recurrence. Similar to epithelial ovarian cancers 
the presenting symptoms of granulosa cell tumors are 
usually nonspecific with abdominal pain (41.1 %) or 
distension (26.4 %) [1]. These patients present with a 
large ovarian mass Hyperestrogenic symptoms occur in 
all age groups. In prepubertal age group, precocious 
puberty will be seen. In the reproductive age group, 
menstural patterns alteration (32.8 %) like 
menorrhagia, intermenstural bleeding or amenorrhoea 
may be seen. Postmenopausal age group 
postmenopausal bleeding is the most common finding. 
Endometrial cancers, usually detected in the 
pathological specimens, are well differentiated early 
stage disease and have a good prognosis. Most of the 
women with early stage GCT require no further 
treatment and have good prognosis 
however,approximately 11%-37%of patients will 
relapse with a median time of 75 months (range 55-
137months) after diagnosis, with one report showing 
recurrence 40 years after initial diagnosis [7,8]. 
Extrapelvic recurrence of granulosa tumor has been 
reported in up to 52% of cases. Therefore long term 
follow up is required. The long term follow up should 
include physical exam as well as tumor marker studies 
including estradiol, inhibin, and mullerian inhibitory 
substance [9]. 
Patients had multiple recurrence of granulosa cell 
tumor associated with a poor prognosis. Most of the 
patient had recurrence within 10 years after the initial 
diagnosis, there are some case reports in which patient 
had recurrence of disease even after 10 years. 
In our case, the patient had relapse multiple time after 
the initial diagnosis. In one case report patient 
 
Asian Pac. J. Health Sci., 2016; 3(1):148-150                                          e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
____________________________________________________________________________________________________________________________________________ 
Chandra  et al                       ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2016; 3(1):148-150 
www.apjhs.com      150 
 
presented with retroperitoneal hemorrhage with 
recurrence after 4 year of initial diagnosis. Once the 
tumor recurs it’s fatal approximately in 80 % cases. 
Park et al found in their study that, none of the patients 
with early stage disease who underwent optimal 
debulking had tumor recurrence and with advanced 
stage of GCT who received at least 6 cycles of BEP 
adjuvant chemotherapy none of the patient had tumor 
recurrence [10]. The longest time of recurrence 
reported in study is 40 years. Sun et al found in their 
study that about 21 % develop recurrence and the 
median time to relapse was 57.6 months (2–166 
months) [11]. Aburustum et al [12] reported that local 
pelvic recurrence occurs in 70% cases, 9% recurrence 
occurs in pelvis and abdomen, 6% occurs in 
retroperitoneum, 6% pelvis and retroperitoneum and 
3% had recurrence in pelvis, abdomen and 
retroperitoneum. It has been found that most 
recurrences of peritoneal is suggestive of possibility of 
missed peritoneal disease during primary surgery 
especially for early stage disease. According to a study 
by Fotopoulou et al. dissemination of tumor patterns 
differed significantly between primary and recurrent 
patients, patient having significantly higher rates of 
diffuse peritoneal involvement and extraovarian tumor 
involvement of the middle and upper abdomen in the 
recurrent cases. It has been found in studies that only 
about 85 % of the relapsed patients could be operated 
without residual lesions compared to nearly 100 % in 
all primary patients. Multiple organ involvement with 
metastasis to liver, appendix and intestines are quite 
common while metastases to lung, bone, vagina, 
adrenal, spleen, pancreas, gall bladder, rectus muscle 
are rarely reported. 
 
Conclusion 
So due to high chance of recurrence even years after 
apparent clinical cure of the primary tumor, lifelong 
follow up  of patient with clinical examination and 
tumor markers like inhibin B is recommended. 
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